ECM Biomaterials Platform
Trylle Biologics develops engineered extracellular matrix biomaterials enabling programmable tissue architectures, advanced biofabrication, and resilient biologic supply chains.
One platform. Multiple high-value applications — from neural interfaces that truly integrate with human tissue to cell therapies that work in challenging deployment scenarios.
Platform Overview
Founded by biomaterials veterans with 74+ combined patents, our tunable hybrid biomaterial system uses human collagen from cultured fibroblasts to achieve what synthetic materials cannot. The platform combines human atelopeptide collagen with advanced CMC-polymer systems to produce materials with precisely adjustable rheological properties, enhanced thermal stability including autoclave survivability, and superior biocompatibility. The same core process enables functionalization with other human ECM proteins and integration of biological actives including antibodies, growth factors, and cytokines. Core innovations are protected by US Provisional patents.
Manufacturing Infrastructure
Our platform is designed for seamless integration with established CDMO partners providing GMP-grade bioreactor systems for scalable human collagen production, enabling rapid scale-up without capital-intensive infrastructure investment while maintaining regulatory compliance and government contracting readiness.
CDMO capabilities include off-the-shelf bioreactor systems optimized for human cell culture, scalable production from research to commercial volumes, GMP-compliant facilities with validated processes, integrated quality control and release testing, and full regulatory documentation support.
Every Trylle application- from neural interfaces to behavioral health devices- builds on this shared GMP manufacturing foundation, reducing development time and regulatory risk across the entire product pipeline.
TBI & Neocortical Repair
Structured Cortical Reconstruction Using Human ECM Technology
Focal neocortical injury from stroke, trauma, or neurodegeneration produces irreversible functional loss because adult cortex lacks the developmental framework required for organized structural reconstruction.
Our breakthrough approach uses structurally engineered neocortical precursor tissue defined by multi-omics mapping and controlled extracellular matrix architecture rather than cellular differentiation alone.
Technical Innovations:
• iPSC-derived neural and mesenchymal progenitors
• Embedded in tunable human collagen-CMC backbone
• Replicates developmental ECM composition
• Engineered for laminar cytoarchitecture restoration
Brain-Machine Interface (BMI)
Our cutting-edge Brain-Machine Interface (BMI) technology represents the next frontier in medical innovation. Utilizing our human collagen platform, this device enhances neural interfaces, enabling groundbreaking applications in neurology and prosthetics.
Our neural interfaces leverage the platform's unique thermal stability and biocompatibility. Unlike synthetic polyimides, our tunable human ECM materials truly integrate with neural tissue, enabling long-term stability impossible with conventional approaches.
Key Advantages:
• Superior tissue integration
• Reduced immune response
• Extended operational lifespan
• Defense-grade reliability
Manufacturing an All Natural Neural Interface for Ultra High Density Arrays
Our Goal is a biological BMI with Tissue-like Channel Density
Ambient Biostasis Platform for Cell Therapy Storage and Delivery
ANCHOR Qualification Infrastructure
Adaptive Native Collagen Hydrogel for Organ Readiness
The applications described above- from neural interfaces to ambient biostasis- all depend on a consistent, translation-ready supply of human biomaterial inputs. ANCHOR is the shared qualification infrastructure that makes that supply chain defensible at scale.
Developed as a qualification framework for advanced bioprinting applications, ANCHOR enables multiple research and development teams to transition from animal-derived collagen sources to human ECM inputs without rebuilding their validation processes from scratch. By establishing standardized qualification protocols, material characterization benchmarks, and GMP-compatible processing pathways, ANCHOR addresses the bottleneck that has prevented widespread adoption of human collagen in next-generation biomedical applications.
Trylle's current ANCHOR development focus is liver tissue bioprinting — establishing human ECM qualification infrastructure compatible with embedded bioprinting platforms operating under ARPA-H's bioprinting initiative. The 18-month work plan is designed to produce qualification data that benefits not only Trylle's own product pipeline but the broader field of human biomaterial translation.
ANCHOR is not a product. It is the infrastructure that makes Trylle's products possible at clinical and commercial scale- and that positions the platform for the manufacturing readiness requirements that government program milestones demand.
A 510k FDA Approval Pathway:
Prostate Cancer Hydrogel Spacer
Our Prostate Cancer Hydrogel Spacer represents strategic platform validation through the FDA 510(k) pathway. This injectable device reduces radiation exposure during prostate cancer treatment, requiring only animal studies rather than human clinical trials for expedited regulatory approval.
Platform Strategy: This 510(k)-cleared product validates our tunable human collagen technology while establishing GMP manufacturing capabilities and FDA regulatory credibility. Success with this streamlined approval pathway creates regulatory momentum for more complex applications including neural interfaces and advanced biomedical devices.
The spacer leverages our platform's biocompatibility advantages, providing a non-inflammatory, natural-tissue-like medium that demonstrates our human ECM technology's safety and efficacy to regulatory authorities.
Prostate cancer is the most common cancer diagnosed in the VA system, accounting for roughly 30% of all new cancer cases with
approximately 15,000 new diagnoses and over 200,000 survivors treated annually. Veterans are twice as likely to be diagnosed with prostate cancer compared to the general population.
At Trylle Biologics, we are not just creating products; we are shaping the future of biomedical innovation.
Our commitment to breakthrough science, rigorous validation, and translational impact drives everything we do. Whether you are a biomedical researcher, government program manager, investor, or development partner, we invite you to join us in advancing applications that solve problems synthetic materials cannot address.
Contact Us
For more information about our products, services, or investment opportunities, please reach out to us at info@trylleinc.com.
The Prostate Cancer Gel Spacer protects the rectum from radiation side effects that are almost as bad as the cancer
The market is approximately $250M and growing with the incidence of Prostate Cancer
Cell therapies represent some of the most promising advances in regenerative medicine — and some of the most fragile. Conventional cell therapy products require continuous cold chain management, specialized handling equipment, and administration within hours of preparation. These constraints make them effectively inaccessible in forward operating environments, austere clinical settings, disaster response scenarios, and long-duration space missions where refrigeration cannot be guaranteed.
Trylle's Ambient Biostasis Platform solves the cold chain problem at the materials level. Our tunable human collagen ECM system provides a protective biomatrix that maintains cell viability at ambient temperatures — 20–25°C — for extended periods without cryogenic infrastructure. This is not a packaging improvement. It is a fundamental shift in how cell therapies can be stored, transported, and delivered.
The platform uses a dual-chamber cartridge architecture that keeps the biomaterial matrix and the therapeutic cell population separated until the moment of administration, preserving viability while enabling simple, field-compatible deployment. No specialized training, no cold storage logistics, no time-critical administration window.
Defense and space applications are primary development targets- neural progenitor therapies for TBI treatment in forward operating environments, cell-based wound repair for austere settings, and biologics delivery for extended missions beyond reliable supply chains.
The same platform also addresses civilian applications where cold chain failure is a persistent barrier to equitable access to advanced cell therapies.
